In this issue of JAMA Psychiatry, the study by Samara et al1 provides an important update on the evidence surrounding clozapine as the treatment of choice for those individuals with schizophrenia that is considered resistant to other medications. The authors indicate that as many as one-third of patients with schizophrenia experience persistent psychotic symptoms despite adequate treatment with antipsychotics. Therefore, the management of schizophrenia in these patients represents a major public health challenge in human and economic terms.
Kane JM, Correll CU. The Role of Clozapine in Treatment-Resistant Schizophrenia. JAMA Psychiatry. 2016;73(3):187-188. doi:10.1001/jamapsychiatry.2015.2966